Shots:
- GSK to acquire Boston’s lead asset, efimosfermin alfa, a P-III candidate for steatotic liver disease (SLD)
- As per the deal, GSK will acquire BP Asset IX (Boston’s subsidiary) for ~$2B to access efimosfermin, incl. $1.2B upfront & $800M in milestones, plus GSK will also be responsible for royalties & milestone payments owed to Novartis
- Efimosfermin alfa along with GSK’s human genetics insights, shows potential in advanced SLD & in combination with GSK’990, expanding GSK’s hepatology pipeline with possible 1st launch in 2029. Also, P-II data in biopsy-confirmed F2/F3 MASH pts showed rapid, significant liver fibrosis reversal & progression prevention; full data was shared at AASLD 2024
Ref: GSK | Image: GSK and Boston Pharmaceuticals | Press Release
Related News:- GSK Reports the P-III (GLISTEN) Study Results of Linerixibat for Primary Biliary Cholangitis (PBC) Patients with Cholestatic Pruritus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
